Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BPI-21668 in Advanced Solid Tumor Patients
NCT05341570Phase 1Unknown
- Sponsor
- Betta Pharmaceuticals
- Start
- Jan 2022
- Primary completion
- Jan 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of BPI-21668 in solid tumor (2 arms), sponsored by Betta Pharmaceuticals. Primary endpoints: Adverse Events, Maximum Tolerated Dose and 1 more. Status: unknown.
02
Drugs
BPI-21668
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT05341570.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05341570.